On November 19, 2018, the FDA submitted a proposal to the White House Office of Management and Budget (OMB) to approve a review that will assess current communication practices between FDA review staff and Investigational New Drug (IND) sponsors. The FDA has contracted with Eastern Research Group (ERG) to determine whether the current mode of communication between these parties needs to be adapted moving forward. Depending on the results of this review, communication practices and requirements could be altered, which might have an effect on the IND application process. Possible ...
Blog Editors
Recent Updates
- Podcast: Can Food Really Be Medicine? Transforming Health Care One Bite at a Time – Diagnosing Health Care
- The Civil Commitment Executive Order: Mixed Messages for Behavioral Health Stakeholders, State, and Local Governments
- AI Infrastructure, Ideology, and Exports: Inside the White House’s New AI Orders
- Texas Judge Strikes Down HIPAA’s Reproductive Health Amendment
- White House AI Action Plan Drops: Here’s What We Know